Bimagrumab: the muscle-sparing GLP-1 partner

As the American Diabetes Association's 86th Scientific Sessions open June 5–8, the quality of weight loss — not just the quantity — has become a headline theme, and no compound illustrates it better than bimagrumab. The BELIEVE trial, published in Nature Medicine on March 5, 2026, paired bimagrumab with semaglutide and showed something a strength audience should care about: you can strip fat while actively sparing, or even building, muscle. For lifters worried about the lean-mass cost of GLP-1 drugs, it's the most direct evidence yet that the muscle-loss problem is solvable.

What happened

BELIEVE was a Phase 2, 72-week trial testing bimagrumab and semaglutide alone and in combination in adults with obesity. The body-composition results are the point:

The standout numbers: semaglutide alone delivered more total weight loss than bimagrumab, but a meaningful chunk of it — nearly 30% — came from lean tissue. Bimagrumab alone produced less weight loss but actually increased lean mass by 2.5% while taking the loss almost entirely from fat. Combined, the two delivered the largest total loss (22.1%) with the great majority of it (92.8%) coming from fat.

Bimagrumab is an antibody that blocks activin signaling — the same broad pathway that includes myostatin, the brake on muscle growth. By blocking it, bimagrumab pushes the body to retain and build muscle, which is why it counteracts the lean-mass loss that comes with aggressive GLP-1-driven dieting. The combination was generally well tolerated, though researchers flagged mild-to-moderate acne and muscle spasms in the bimagrumab groups as issues needing further study.

Why it matters

This is the mirror image of the concern we keep raising about the whole GLP-1 class. In tirzepatide muscle loss: what lifters can do and keeping lean mass on a GLP-1 stack, the core problem is that powerful appetite suppression strips muscle along with fat unless you actively defend it. Bimagrumab attacks that problem pharmacologically — instead of relying solely on protein and training to protect muscle, it blocks the activin/myostatin pathway to preserve it directly.

It's also a real-world data point on the myostatin-pathway drugs that have historically disappointed. Bimagrumab doing its muscle-sparing job in a large obesity trial is more convincing than the animal-model hype that surrounds research-chemical "myostatin inhibitors" — though note bimagrumab is a clinical antibody in supervised trials, not something sold on a peptide vendor's site. The activin-blocking approach is the same idea behind the failed ACE-031, but bimagrumab has advanced much further with a cleaner risk picture so far.

What to watch

Expect muscle-preservation and "weight-loss quality" to be a recurring theme at ADA 2026, with bimagrumab as the lead example of the pharmacological approach. The open questions are durability and safety beyond 72 weeks — the acne and muscle-spasm signals, plus longer-term tolerability, will determine whether bimagrumab becomes a real combination partner or stalls like earlier activin-pathway drugs. For lifters, the practical takeaway hasn't changed yet: protein and resistance training remain the proven, available way to protect muscle on a GLP-1. Bimagrumab is a promising future tool, not a current one — it's investigational and not approved.

Sources

• Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity — Medical Xpress
• Bimagrumab plus semaglutide for the treatment of obesity: a randomized phase 2 trial — Nature Medicine